StevenMFruchtmanMD

Associate Professor of Hematology & Oncology, New York Medical College

Dr. Fruchtman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
863 Riverside Dr
Suite 1 Fw
New York, NY 10032
Phone+1 201-310-1634

Fax+1 212-996-8034

Dr. Steven Fruchtman is a hematology specialist based in New York, NY, with an educational background from New York Medical College and advanced training in internal medicine and hematology/medical oncology. His clinical expertise includes thrombocytopenia, myeloproliferative disorders, bone marrow failure syndromes, aplastic anemia, and bone marrow transplantation. Dr. Fruchtman has contributed to numerous research publications, including studies on rigosertib in myelodysplastic syndromes and acute myeloid leukemia. He has been recognized multiple times by Castle Connolly as one of America's Top Doctors and Top Doctors in the New York Metro Area.

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1981 - 1983
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1977 - 1981
New York Medical CollegeClass of 1977

PubMed

17 citations
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
Shyamala C. Navada, Guillermo Garcia-Manero, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado
Leukemia Research. 2020-05-12
9 citations
Proceedings of the fifth international RASopathies symposium: When development and cancer intersect
Katherine A. Rauen, Lisa Schoyer, Lisa Schill, Beth Stronach, John G. Albeck
American Journal of Medical Genetics. Part A. 2018-12-01
34 citations
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Shyamala C. Navada, Steven M. Fruchtman, Rosalie Odchimar-Reissig, Erin P. Demakos, Michael E. Petrone
Leukemia Research. 2018-01-01

Abstracts/Posters

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...
Steven M. Fruchtman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial CancerMay 12th, 2023
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial CancerMay 11th, 2023
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
Join now to see all